GYRE THERAPEUTICS Business Summary

Gyre Therapeutics, Inc. operates as a commercial-stage biopharmaceutical firm primarily generating revenue through the sale of its proprietary anti-fibrotic medication, Hydronidone (marketed as Etuary), via its majority-owned subsidiary, Beijing Continent Pharmaceutical. The company’s business model centers on a vertically integrated approach in China, encompassing large-scale manufacturing and a robust direct sales infrastructure, while simultaneously pursuing a licensing and clinical development strategy for its F351 candidate in the U.S. and other global markets. Gyre’s primary business segments are divided into commercialized fibrosis treatments and a diversified R&D pipeline targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Chronic Hepatitis B-induced liver fibrosis. Its direct competitors include Boehringer Ingelheim, Roche, and Pliant Therapeutics; Gyre maintains a competitive advantage through its established market dominance in the Chinese idiopathic pulmonary fibrosis sector and a cost-efficient manufacturing base that provides superior margins relative to Western biotechnology peers. The leadership team is led by Chief Executive Officer Rodney Riggs, a veteran healthcare executive with extensive experience in commercial operations, and Chief Financial Officer Justin Renz, who previously held senior leadership roles at Catalyst Biosciences and Karyopharm Therapeutics. The company’s strategic vision is guided by Chairman Dr. Ying Luo, the founder of GNI Group and a prominent figure in international biotechnology with a background in molecular biology. Gyre is backed by its majority shareholder, GNI Group Co., Ltd., a publicly traded entity on the Tokyo Stock Exchange, which provides significant capital resources and strategic alignment across the Pan-Pacific region. The Board of Directors includes seasoned industry experts such as Dr. Charles J. Cohen, ensuring the company maintains high standards of corporate governance and scientific excellence as it transitions from a regional leader to a global biopharmaceutical player.